Esophageal cancer: Clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Stahl, M ^a   Budach, W ^b   Meyer, H J ^c   Cervantes, A ^d  

^a KLINIKEN ESSEN MITTE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c STÄDTISCHES KLINIKUM SOLINGEN   (Germany)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FOLLOW UP; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

EID: 77954323877     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq163     Document Type: Article

References (20)

1. Bosetti C, Bertuccio P, Levi F et al. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008; 19: 631-640.
2. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507.
3. Arnott SJ, Duncan W, Gignoux M et al. Preoperative radiotherapy for esophageal carcinoma. The Cochrane Library 2003, Issue 1.
4. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
5. Boige V, Pignon J, Rougier B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus: FNLCC ACCORD 07 - FFCD 9703 trial. J Clin Oncol 2007; 25 (Suppl): (Abstr 4510).
6. Ell C, May A, Pech O et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007; 65: 3-10.
7. Boone J, Livestro DP, Elias SG et al. International survey on esophageal cancer: part I surgical techniques. Diseases Esophgus 2009; 22: 195-202.
8. Omloo JMT, Lagarde SM, Hulscher JBF et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus. Five-year results of a randomized clinical trial. Ann Surg 2007; 246: 992-1001.
9. Fiorca F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53: 925-930.
10. Gebski V, Burmeister B, Smithers BM et al. Survival benefit from neoadjuvant chemoradiotherapy or chemotherapy in esophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234.
11. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-1092.
12. Stahl M, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856.
13. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174.
14. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317.
15. Bedenne L, Michel P, Bouche O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168.
16. Crehange G, Maingon P, Peignaux K et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: FFCD 9102. J Clin Oncol 2007; 25: 4895-4901.
17. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
18. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V-325 study group. J Clin Oncol 2006; 24: 4991-4997.
19. Lordick F, Ott K, Krause B.-J. et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophago-gastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805.
20. Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in firstline human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27:18s (suppl.): (Abstr LBA 4509).